Latif Karahan

Dr. Latif Karahan

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LKLatif Karahan
Latif Karahan
AAArif Akyildiz
Arif Akyildiz
TSTaha Koray Sahin
Taha Koray Sahin
MBMUSTAFA ARDA BATU
MUSTAFA ARDA BATU
CECagatay Ersan
Cagatay Ersan
DGDeniz Can Guven
Deniz Can Guven
Background/Objectives: Sarcopenia, defined by reduced skeletal muscle mass, may have prognostic relevance in metastatic breast cancer. Muscle quality, reflected by adipose tissue indices, could also influence outcomes, but evidence in CDK4/6 (cyclin-dependent kinase)-inhibitor-treated patients is limited. We therefore evaluated the prognostic impact of baseline sarcopenia and adipose tissue distribution indices in this population. Methods: We retrospectively analyzed 156 women with HR+/HER2− MBC (hormone-receptor-positive, Her2-negative metastatic breast cancer) who initiated ribociclib or palbociclib plus endocrine therapy between May 2020 and January 2024. Association between L3 computed tomography (CT)-derived skeletal muscle index (SMI) and adipose tissue indices was evaluated with univariable and multivariable analyses. Sarcopenia was defined as SMI < 41 cm2/m2. Results: Median age was 57.6 years; 75% of patients were postmenopausal, and 48% of the cohort were sarcopenic. Median progression-free survival (PFS) for the entire cohort was 24.7 months (95% CI: 20.3–29.2). Patients with baseline sarcopenia had substantially shorter PFS compared to those without sarcopenia (21.5 months (95% CI: 10.9–32.1), versus 27.1 months (95% CI: 15.2–39; p = 0.016). Multivariable Cox regression analyses identified two independent predictors of prolonged PFS: non-sarcopenia (SMI ≥ 41 cm2/m2) and de novo metastatic disease. BMI (body mass index) and all adipose indices were not associated with PFS. Conclusions: Baseline non-sarcopenia and de novo metastatic disease independently predict longer PFS on CDK4/6 inhibitors, whereas adiposity measures and BMI are not prognostic. Routine body composition assessment may refine risk stratification and identify candidates for supportive interventions. Prospective studies are needed to validate these findings.

1 March 2024 in Medicine
Verified
Journal Article
Open access
NDNebi Serkan Serkan Demirci
Nebi Serkan Serkan Demirci
AAAbdulmunir Azizy
Abdulmunir Azizy
NPNail Paksoy
Nail Paksoy
IDIzzet Dogan
Izzet Dogan
SKSenem Karabulut
Senem Karabulut
DTDidem Tastekin
Didem Tastekin
The prognosis of metastatic gastric cancer (GC) is poor, with a median survival time of less than a year. Capecitabine is a prodrug, metabolized by thymidine phosphorylase to its cytotoxic metabolite (5-FU). Few studies have compared capecitabine and 5-FU in mGC. In this retrospective study, we compared the efficacy and safety of modified DCF (mDCF) (docetaxel, cisplatin, and 5-FU) and modified DCX (mDCX) (docetaxel, cisplatin, and capecitabine) regimens for first-line treatment in patients with mGC. The study included 112 mGC patients treated with either mDCF (n = 69) or mDCX (n = 43) between 2010 and 2021. Demographic data, response rate, progression-free survival (PFS), overall survival (OS), and adverse events were evaluated. The complete response rate in the mDCF group was 10.1%, whereas the complete response rate in the mDCX group was 2.3%. The partial response rate for mDCF and mDCX were 29% and 37%, respectively. The 2 treatment arms of the study had the same objective rate of response and disease control rate (DCR). PFS and OS rates were comparable between the 2 groups. The median PFS in the mDCF and mDCX arms were 6.0 months (95% CI, 4.87–7.14) and 5.0 months (95% CI, 4.10–5.90) respectively (P = .08). The median OS in the mDCF and mDCX arms were 9.0 months (95% CI, 7.53–10.47) and 9.0 months (95% CI, 6.87–11.11) respectively (P = .07). Neutropenia, asthenia, stomatitis, and nausea/vomiting were the most frequently reported grade 3 to 4 adverse events (AEs). The rates of grade 3/4 AEs and dose reduction were comparable between the 2 groups. There was no treatment discontinuation due to grade 3 to 4 AE. As a first-line treatment for patients with mGC, mDCX and mDCF regimens have comparable efficacy and tolerability profiles.

14 April 2026 in Scientific Reports
Verified
Journal Article
Open access
GAGözde Ağdaş
Gözde Ağdaş
DGduygu bayır garbioglu
duygu bayır garbioglu
ESElif Sahin
Elif Sahin
MCMuhammet Cengi̇z
Muhammet Cengi̇z
DGDeniz Can Guven
Deniz Can Guven
IKibrahim karadağ
ibrahim karadağ
Immune checkpoint inhibitors such as nivolumab have brought meaningful benefits to patients with advanced non-small cell lung cancer (NSCLC), yet many patients still experience limited responses. Vitamin D is a key modulator of immune function, and deficiency is common in individuals with cancer. Given its potential role in shaping immunotherapy response, we retrospectively assessed whether baseline vitamin D levels were associated with clinical outcomes in advanced NSCLC patients treated with nivolumab. We retrospectively analyzed patients with stage IV NSCLC treated with nivolumab across multiple centers, predominantly as second-line therapy. Prior to nivolumab initiation, all patients were confirmed to be negative for common driver mutations, including EGFR, ALK, ROS1, and other actionable genomic alterations. Baseline serum 25-hydroxyvitamin D levels were measured prior to nivolumab initiation, and patients were categorized as having severe deficiency (< 10 ng/mL), deficiency (10–20 ng/mL), or sufficient levels (≥ 20 ng/mL). The presence of liver metastases was recorded at baseline. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared with log-rank tests. Multivariable Cox proportional hazards models adjusted for age, sex, ECOG performance status, liver metastasis, and other metastatic sites were used to evaluate the independent prognostic value of vitamin D status. Objective response rates (ORR) were assessed in patients with available radiologic data. A total of 890 patients were screened, and after excluding those with missing baseline vitamin D data, 305 patients were included in the analysis. The median age was 64 years (range 34–85), and 68% of patients were male. Vitamin D levels were < 10 ng/mL in 30%, 10–20 ng/mL in 44%, and ≥ 20 ng/mL in 26% of patients. Patients with severe vitamin D deficiency were numerically older (median age 65 vs. 63 years) and had higher rates of ECOG PS ≥ 2 (15.1% vs. 7.5%) and squamous histology (37.6% vs. 27.5%), though these differences were not statistically significant (p > 0.05 for all). Liver metastases were present in 54 patients (17.7%), and the distribution was similar across vitamin D groups (p = 0.92). Median PFS was shortest in patients with severe vitamin D deficiency (3.4 months), intermediate in the 10–20 ng/mL group (5.2 months), and longest in patients with sufficient levels (8.1 months). Median OS ranged from 8.6 months in the < 10 ng/mL group to 15.8 months in the ≥ 20 ng/mL group. Patients with liver metastases had significantly shorter OS compared to those without (median OS 9.8 vs. 13.6 months, HR 1.48, p = 0.006). Vitamin D deficiency was associated with significantly worse PFS and OS on univariate analysis. In multivariable analysis, vitamin D levels < 20 ng/mL remained independently associated with poorer OS. ORR was numerically higher in patients with sufficient vitamin D levels (30% vs. 14%). Lower baseline vitamin D levels were associated with inferior clinical outcomes in advanced NSCLC patients treated with nivolumab. Patients with vitamin D levels ≥ 20 ng/mL demonstrated longer PFS and OS and a trend toward higher response rates. These findings support a prognostic role for vitamin D status in immunotherapy-treated NSCLC; however, prospective studies are required to determine whether vitamin D optimization can causally enhance immunotherapy efficacy.

8 May 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MCMuhammet Cengi̇z
Muhammet Cengi̇z
OBOKTAY BOZKURT
OKTAY BOZKURT
ACAyse NURANSOY Cengiz
Ayse NURANSOY Cengiz
DGDeniz Can Guven
Deniz Can Guven
ESElif Sahin
Elif Sahin
MOMetin Ozkan
Metin Ozkan
Nivolumab is currently widely used in the treatment of lung cancer. Studies have been conducted using flat doses of 240 mg and 3 mg/kg. In fact, studies involving a small number of patients have begun to explore low-dose immunotherapies. The literature on the optimal dose of immunotherapy, the use of weight based, or fixed doses is very recent and has become a one of the subject of ongoing research. This multicenter study included 716 patients with NSCLC. Patients receiving standard doses of 3 mg/kg and 240 mg of nivolumab were divided into subgroups based on their weight. Patients weighing 80 kg have already received a flat dose. However, patients weighing < 80 kg who received a flat dose were considered to be receiving high-dose therapy. Conversely, patients weighing more than 80 kg who received a flat dose were maintained on a low dose. Therefore, overall survival, progression-free survival, and toxicity were examined according to weight-based usage. The median progression free survival (PFS) for those receiving a 3 mg/kg dose was 6 months, whereas it was 9.8 months for those receiving a flat dose (p < 0.001). The median (metastatic overall survival) OS for those receiving a 3 mg/kg dose was 12 months, whereas it was 14 months for those receiving a 240 mg dose (p = 0.03). This study was based on real-world data. Therefore, our results may be instructive regarding the nivolumab dose, which is a commonly used treatment for NSCLC patients. Our results suggest that a flat dose may be preferred in all groups and as a subgroup, especially in patients weighing < 80 kg.

20 June 2025 in Acta Medica
Verified
Journal Article
Open access
PDF file
OBonur bas
onur bas
MTMert Tokatlı
Mert Tokatlı
NGNaciye Güdük
Naciye Güdük
LKLatif Karahan
Latif Karahan
TSTaha Koray Sahin
Taha Koray Sahin
SASercan Aksoy
Sercan Aksoy
Background: The objective of this study is to assess the correlation between survival outcomes and fibrosis-4 (FIB-4) index in patients with non-metastatic breast cancer treated with anthracyclines Methods: This study was conducted on individuals with non-metastatic breast cancer who were treated with at least one dose of anthracycline from 2018 to 2023. The FIB-4 index was calculated based on the following parameters: age, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) serum levels, and platelet count for each patient before anthracycline treatment. Results: A total of 208 patients were included in the study. Patients below 35 years of age (n=28) and those above 65 years of age (n=11) were excluded from the study as the FIB-4 index is less reliable in these age groups. Patients were then divided into two subgroups, low and high, according to the pre-defined cut-off value of 1.45, which is obtained from the primary reference. In univariate analysis, hemoglobin (p=0.03), FIB-4 index (p=0.02), and diagnosis at stage (p=0.01) were statistically related to overall survival (OS). In multivariate analysis, patients with higher FIB-4 index (HR: 4.36, 95% CI 1.38-13.78 p=0.012), anemia (HR: 3.32, 95% CI 1.32-8.34, p=0.011), and stage 3 (HR: 4.53, 95% CI 1.22-16.76, p=0.024) had decreased OS. An additional aim was to evaluate the association between anthracycline-induced cardiotoxicity and the FIB-4 index. Our study showed no relationship (p=0.738). Conclusions: The FIB-4 index, a marker easily obtained through routine biochemistry testing at low cost, could serve as an independent predictor of OS patients with non-metastatic breast cancer treated with anthracyclines. Routine lab tests performed for cancer patients may help clinicians identify high-risk patients in whom closer follow-up or protective measures should be considered.

Verified
Journal Article
Open access
PDF file
ACAysegul Merc Cetinkaya
Aysegul Merc Cetinkaya
MYMEHMET HALUK YÜCEL
MEHMET HALUK YÜCEL
LKLatif Karahan
Latif Karahan
MEMustafa Ersoy
Mustafa Ersoy
ABAhmet Bilici
Ahmet Bilici
SGsema sezgin goksu
sema sezgin goksu
Background: Immune checkpoint inhibitors (ICIs) such as nivolumab have transformed the treatment landscape of metastatic non-small cell lung cancer (NSCLC). We aimed to evaluate survival outcomes of patients who developed immune-related adverse events (irAEs) that required permanent treatment discontinuation. Methods: This national, multicenter study included 25 patients with metastatic NSCLC from four tertiary oncology centers in Turkey. All patients received nivolumab monotherapy and discontinued treatment because of irAEs. Long-term survival was analyzed using Kaplan–Meier methods and compared indirectly with historical benchmarks. Results: The median overall survival (OS) was 35.73 months (95% CI: 30.06–41.40). The 2-year and 5-year OS rates were 78.9% and 27.0%, respectively. Median progression-free survival (PFS) was 16.23 months. Pneumonitis was the most frequent irAE (48%). Liver metastases significantly reduced OS (23.93 vs. 38.50 months, p = 0.005). In univariate analysis, ECOG 2 status (HR:22.07), bone metastases (HR:3.52), and subsequent systemic therapy (HR:30.19) weresignificant predictors of progression. Conclusions: Patients with metastatic NSCLC who discontinue nivolumab due to irAEs achieve notable survival outcomes, suggesting that treatment-limiting toxicity may signal a robust and durable antitumor immune response. These findings, though limited by a small cohort, highlight a distinct responder phenotype in real-world clinical practice.